Results 91 to 100 of about 36,486 (260)

Patient and hospitalization differences in incarcerated versus nonincarcerated men: Insights from a 10‐year cohort study

Journal of Hospital Medicine, EarlyView.
Abstract Background The incarcerated population in the United States is underserved and aging rapidly; there is a dearth of information regarding their health, including hospital care. Epidemiological information is crucial to guide policymakers’ planning.
Farah Acher Kaiksow, Amir Forati, Kristin Merss, Karen Reece, Marguerite Burns, Eduard Eric Vasilevskis   +5 more
wiley   +1 more source

Assessing buprenorphine treatment utilization and SAMHSA DATA waiver provider distribution in 2021: a real-world analysis in California

Scientific Reports
Qualified clinicians previously required a practitioner waiver (i.e., “DATA-waiver” or "X-waiver") to offer buprenorphine, a medication for opioid use disorder (OUD).
Yun Wang, Tao Hu, Chih-Hung Chang, Matthew Heshmatipour, Jeff Jianfei Guo, Moom R. Roosan, Karen A. Miotto   +6 more
doaj   +1 more source

Evaluating Sleep Apnea: In‐Lab Versus at‐Home Recording Time and the Impact of Positional Disease

The Laryngoscope, EarlyView.
We evaluated the minimum recording time needed for in‐lab polysomnography (PSG1) and home sleep apnea test Type 3 portable monitoring (HSAT) to accurately reflect the full‐night apnea–hypopnea index (AHI) in patients with suspected obstructive sleep apnea (OSA).
Raquel Chartuni Pereira Teixeira, Michel Burihan Cahali   +1 more
wiley   +1 more source

Targeting recovery capital for adolescents through treatment for opioid use disorder: a pilot expansion of the Youth Opioid Recovery Support intervention

Frontiers in Adolescent Medicine
BackgroundYouth Opioid Recovery Support (YORS) is a multi-component behavioral treatment approach for youth with opioid use disorder (OUD) with known efficacy on adherence to injectable medications for OUD (MOUD) in young adults. YORS has not been tested
Lexi Taylor, Kevin Wenzel, Kamala Mallik-Kane, Christopher Pfeltz, Elise Massie, Katherine Davis, Luciana Lavorato, Marc Fishman, Marc Fishman   +8 more
doaj   +1 more source

Postoperative Effects of Celecoxib on Opioid Use and Pain Control After Benign Oropharyngeal Surgery

The Laryngoscope, EarlyView.
This study evaluated how the addition of celecoxib to a multimodal pain regimen following tonsillectomy + adenoidectomy, or uvulopalatopharyngoplasty (UPPP) + tonsillectomy affects postoperative opioid use and pain control. Patients who received celecoxib consumed significantly fewer opioids compared to the historic control group, with similar ...
Alana Platukus, Praneet Kaki, Anastasia Kaffenes, Udeerna Tippabhatla, Jared Robinson, Jaehee Kim, Erin Creighton, Meghan Crippen, Maurits Boon, Colin Huntley   +9 more
wiley   +1 more source

Osteoarthritis: An Immuno‐Inflammatory Disease‐Mechanisms of Immune Cell Dysregulation and Potential Therapeutic Strategies

Med Research, EarlyView.
This review summarizes the immuno‐inflammatory mechanisms driving the pathogenesis of osteoarthritis (OA), extending beyond the traditional view of OA as a purely degenerative disease to incorporate immune cell infiltration, inflammatory factor release, and the formation of a chronic low‐grade inflammatory microenvironment.
Qingqiang Lei, Xiaoxian Lou, Xu Su, Shubao Liu, Yanli Tong, Jie Chen, Xuerui Chen, Wenjun Mao, Hui Yu, Liangbin Lin   +9 more
wiley   +1 more source

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study

Movement Disorders, EarlyView.
Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Monica M. Kurtis, Alexander Storch, José‐Francisco Rocha, Raquel Costa, Diogo Magalhães, Guillermo Castilla‐Fernández, Helena C. Brigas, Joerg Holenz, Per Odin, on behalf of the OCEAN study group   +13 more
wiley   +1 more source

Real-world effectiveness of medication-assisted treatment and psychotherapy for opioid use disorder: a national multi–health care organization analysis

Frontiers in Psychiatry
BackgroundHarm reduction strategies for opioid use disorder (OUD) emphasize pragmatic, evidence-based approaches that reduce overdose risk, relapse, and other adverse outcomes without requiring abstinence.
Nicholas M. Graziane
doaj   +1 more source

Availability of Medications for Opioid Use Disorder in US Psychiatric Hospitals

JAMA Network Open
This cross-sectional study examines the availability of medications for opioid use disorder in psychiatric hospitals in the US.
Cohen, Shawn M., Beetham, Tamara, Fiellin, David A., Muvvala, Srinivas B.   +3 more
openaire   +2 more sources

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source